Race Oncology Welcomes Positive Pre-IND Meeting For Zantrene| MENAFN.COM

Saturday, 03 December 2022 07:11 GMT

Race Oncology Welcomes Positive Pre-IND Meeting For Zantrene


(MENAFN- News Direct)

Melbourne, Victoria | November 24, 2022 11:20 AM Eastern Standard Time


Race Oncology Ltd (ASX:RAC) chief scientific officer Dr Daniel Tillett speaks with Proactive soon after receiving confidential and constructive guidance during a pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration (FDA) for its asset Zantrene (bisantrene dihydrochloride). An IND is the prerequisite to clinical trials in the United States and a key step in the process of obtaining a new drug application (NDA) and marketing approval for a new drug.


MENAFN25112022005728012573ID1105231014


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.